U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C14H19Cl2NO2
Molecular Weight 304.212
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CHLORAMBUCIL

SMILES

OC(=O)CCCC1=CC=C(C=C1)N(CCCl)CCCl

InChI

InChIKey=JCKYGMPEJWAADB-UHFFFAOYSA-N
InChI=1S/C14H19Cl2NO2/c15-8-10-17(11-9-16)13-6-4-12(5-7-13)2-1-3-14(18)19/h4-7H,1-3,8-11H2,(H,18,19)

HIDE SMILES / InChI
Molecular Formula C14H19Cl2NO2
Molecular Weight 304.212
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Chlorambucil is a bifunctional 12 alkylating agent of the nitrogen mustard type that has been found active against selected human 13 neoplastic diseases. Chlorambucil alkylates and cross-links DNA during all phases of the cell cycle, inducing DNA damage via three different methods of covalent adduct generation with double-helical DNA. Bone marrow suppression (anemia, neutropenia, thrombocytopenia) is the most commonly occurring side effect of chlorambucil. There are no known drug/drug interactions with chlorambucil.

CNS Activity

CNS Penetrant
2588
Curator's Comment: Data in rats only. Chlorambucil is ionized at physiological pH and thus minimally enters brain, with a brain/plasma concentration of only 0.02.

Originator

Approval Year

1957
118
Targets

Targets

Primary TargetPharmacologyConditionPotency
Crosslinking Agent
83
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
LEUKERAN

Approved Use

LEUKERAN (chlorambucil) is indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin’s disease. It is not curative in any of these disorders but may produce clinically useful palliation.

Launch Date

1957
Primary
Approved
8583
LEUKERAN

Approved Use

LEUKERAN (chlorambucil) is indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin’s disease. It is not curative in any of these disorders but may produce clinically useful palliation.

Launch Date

1957
Primary
Approved
8583
LEUKERAN

Approved Use

LEUKERAN (chlorambucil) is indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin’s disease. It is not curative in any of these disorders but may produce clinically useful palliation.

Launch Date

1957
Primary
Approved
8583
LEUKERAN

Approved Use

LEUKERAN (chlorambucil) is indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin’s disease. It is not curative in any of these disorders but may produce clinically useful palliation.

Launch Date

1957
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.46 μg/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/6489421
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORAMBUCIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
259 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/6840176
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORAMBUCIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1.99 μg × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/6489421
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORAMBUCIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
380 ng × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/6840176
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORAMBUCIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.94 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/6489421
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORAMBUCIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
DRUG LABEL
https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/967ed3ff-d99b-41e8-b768-dfb586d3d9a6/spl-doc?hl=chlorambucil
CHLORAMBUCIL plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
3.2 mg/kg single, oral
Overdose
Dose: 3.2 mg/kg
Route: oral
Route: single
Dose: 3.2 mg/kg
Sources:
https://pubmed.ncbi.nlm.nih.gov/3065402
healthy, 1.8
Health Status: healthy
Age Group: 1.8
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/3065402
Disc. AE: Irritability, Myoclonic jerks...
AEs leading to
discontinuation/dose reduction:
Irritability
Myoclonic jerks
Exaggerated startle response
Vomiting
Bone marrow depression (mild)
Abnormal EEG
Sources:
https://pubmed.ncbi.nlm.nih.gov/3065402
5 mg/kg single, oral
Overdose
Dose: 5 mg/kg
Route: oral
Route: single
Dose: 5 mg/kg
Sources:
https://pubmed.ncbi.nlm.nih.gov/13462782
healthy, 2.5
Health Status: healthy
Age Group: 2.5
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/13462782
Disc. AE: Convulsive seizure, Comatose...
AEs leading to
discontinuation/dose reduction:
Convulsive seizure
Comatose
Vomiting
Sources:
https://pubmed.ncbi.nlm.nih.gov/13462782
250 mg single, oral
Overdose
Dose: 250 mg
Route: oral
Route: single
Dose: 250 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6655776
healthy, 38
Health Status: healthy
Age Group: 38
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/6655776
Disc. AE: Acute renal failure, Seizures...
AEs leading to
discontinuation/dose reduction:
Acute renal failure
Seizures
Sources:
https://pubmed.ncbi.nlm.nih.gov/6655776
0.2 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.2 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/010669s032lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/010669s032lbl.pdf
Disc. AE: Bone marrow depression, Carcinogenicity...
AEs leading to
discontinuation/dose reduction:
Bone marrow depression
Carcinogenicity
Infertility
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/010669s032lbl.pdf
0.2 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.2 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/010669s032lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/010669s032lbl.pdf
Disc. AE: Convulsions, Metastases...
AEs leading to
discontinuation/dose reduction:
Convulsions
Metastases
Leukemia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/010669s032lbl.pdf
0.2 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.2 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/010669s032lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/010669s032lbl.pdf
Disc. AE: Skin rash, Erythema multiforme...
AEs leading to
discontinuation/dose reduction:
Skin rash (rare)
Erythema multiforme (rare)
Toxic epidermal necrolysis (rare)
Stevens-Johnson syndrome (rare)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/010669s032lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Abnormal EEG Disc. AE
3.2 mg/kg single, oral
Overdose
Dose: 3.2 mg/kg
Route: oral
Route: single
Dose: 3.2 mg/kg
Sources:
https://pubmed.ncbi.nlm.nih.gov/3065402
healthy, 1.8
Health Status: healthy
Age Group: 1.8
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/3065402
Exaggerated startle response Disc. AE
3.2 mg/kg single, oral
Overdose
Dose: 3.2 mg/kg
Route: oral
Route: single
Dose: 3.2 mg/kg
Sources:
https://pubmed.ncbi.nlm.nih.gov/3065402
healthy, 1.8
Health Status: healthy
Age Group: 1.8
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/3065402
Irritability Disc. AE
3.2 mg/kg single, oral
Overdose
Dose: 3.2 mg/kg
Route: oral
Route: single
Dose: 3.2 mg/kg
Sources:
https://pubmed.ncbi.nlm.nih.gov/3065402
healthy, 1.8
Health Status: healthy
Age Group: 1.8
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/3065402
Myoclonic jerks Disc. AE
3.2 mg/kg single, oral
Overdose
Dose: 3.2 mg/kg
Route: oral
Route: single
Dose: 3.2 mg/kg
Sources:
https://pubmed.ncbi.nlm.nih.gov/3065402
healthy, 1.8
Health Status: healthy
Age Group: 1.8
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/3065402
Vomiting Disc. AE
3.2 mg/kg single, oral
Overdose
Dose: 3.2 mg/kg
Route: oral
Route: single
Dose: 3.2 mg/kg
Sources:
https://pubmed.ncbi.nlm.nih.gov/3065402
healthy, 1.8
Health Status: healthy
Age Group: 1.8
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/3065402
Bone marrow depression mild
Disc. AE
3.2 mg/kg single, oral
Overdose
Dose: 3.2 mg/kg
Route: oral
Route: single
Dose: 3.2 mg/kg
Sources:
https://pubmed.ncbi.nlm.nih.gov/3065402
healthy, 1.8
Health Status: healthy
Age Group: 1.8
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/3065402
Comatose Disc. AE
5 mg/kg single, oral
Overdose
Dose: 5 mg/kg
Route: oral
Route: single
Dose: 5 mg/kg
Sources:
https://pubmed.ncbi.nlm.nih.gov/13462782
healthy, 2.5
Health Status: healthy
Age Group: 2.5
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/13462782
Convulsive seizure Disc. AE
5 mg/kg single, oral
Overdose
Dose: 5 mg/kg
Route: oral
Route: single
Dose: 5 mg/kg
Sources:
https://pubmed.ncbi.nlm.nih.gov/13462782
healthy, 2.5
Health Status: healthy
Age Group: 2.5
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/13462782
Vomiting Disc. AE
5 mg/kg single, oral
Overdose
Dose: 5 mg/kg
Route: oral
Route: single
Dose: 5 mg/kg
Sources:
https://pubmed.ncbi.nlm.nih.gov/13462782
healthy, 2.5
Health Status: healthy
Age Group: 2.5
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/13462782
Acute renal failure Disc. AE
250 mg single, oral
Overdose
Dose: 250 mg
Route: oral
Route: single
Dose: 250 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6655776
healthy, 38
Health Status: healthy
Age Group: 38
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/6655776
Seizures Disc. AE
250 mg single, oral
Overdose
Dose: 250 mg
Route: oral
Route: single
Dose: 250 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6655776
healthy, 38
Health Status: healthy
Age Group: 38
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/6655776
Bone marrow depression Disc. AE
0.2 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.2 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/010669s032lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/010669s032lbl.pdf
Carcinogenicity Disc. AE
0.2 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.2 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/010669s032lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/010669s032lbl.pdf
Infertility Disc. AE
0.2 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.2 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/010669s032lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/010669s032lbl.pdf
Convulsions Disc. AE
0.2 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.2 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/010669s032lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/010669s032lbl.pdf
Leukemia Disc. AE
0.2 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.2 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/010669s032lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/010669s032lbl.pdf
Metastases Disc. AE
0.2 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.2 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/010669s032lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/010669s032lbl.pdf
Erythema multiforme rare
Disc. AE
0.2 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.2 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/010669s032lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/010669s032lbl.pdf
Skin rash rare
Disc. AE
0.2 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.2 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/010669s032lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/010669s032lbl.pdf
Stevens-Johnson syndrome rare
Disc. AE
0.2 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.2 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/010669s032lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/010669s032lbl.pdf
Toxic epidermal necrolysis rare
Disc. AE
0.2 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.2 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/010669s032lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/010669s032lbl.pdf
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:28830
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:28830
ChemicalBook
CB5270716
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB5270716
eMolecules
490279
https://www.emolecules.com/cgi-bin/more?vid=490279
MolPort
MolPort-000-152-694
https://www.molport.com/shop/molecule-link/MolPort-000-152-694
ZINC
ZINC000000001115
http://zinc15.docking.org/substances/ZINC000000001115
PubMed

PubMed

TitleDatePubMed
Treatment of membranous nephropathy.
2001
A systematic overview of chemotherapy effects in B-cell chronic lymphocytic leukaemia.
2001
Achieving optimal outcomes in chronic lymphocytic leukaemia.
2001
[Treatment of uveitis with immunosuppressives: antimetabolites and alkylating agents].
2001
Esters of chlorambucil with 2-substituted 1,4-dihydroxy-9,10-anthraquinones as multifunctional anticancer agents.
2001 Apr
Decreased cytotoxicity and increased antimitotic activity of a proline analogue of chlorambucil as a prodrug susceptible to the action of fibroblast's prolidase.
2001 Apr
[Renal involvement in Waldenstroms macroglobulinemia. Case report and review of the literature].
2001 Apr
[Treatment of polycythemia vera].
2001 Apr 6
Reactions of N,N-bis(2-chloroethyl)-p-aminophenylbutyric acid (chlorambucil) with 2'-deoxyguanosine.
2001 Aug
A phase II study of sequential combination chemotherapy with cyclophosphamide, prednisone, and 2-chlorodeoxyadenosine in previously untreated patients with chronic lymphocytic leukemia.
2001 Aug
Stage I and II MALT lymphoma: results of treatment with radiotherapy.
2001 Aug 1
Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011.
2001 Aug 15
Waldenström's macroglobulinemia: clinical course and prognostic factors in 60 patients. Experience from a single hematology unit.
2001 Dec
Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes.
2001 Dec
The Chinese hamster FANCG/XRCC9 mutant NM3 fails to express the monoubiquitinated form of the FANCD2 protein, is hypersensitive to a range of DNA damaging agents and exhibits a normal level of spontaneous sister chromatid exchange.
2001 Dec
[Acute cholestatic hepatitis due to chlorambucil].
2001 Feb
New aspects on the pathogenesis, diagnostic procedures, and therapeutic management of chronic lymphocytic leukemia.
2001 Jan
Cutaneous xanthomas with concurrent demodicosis and dermatophytosis in a cat.
2001 Jul
The effect of optimal treatment on elderly patients with aggressive non-Hodgkin's lymphoma: more patients treated with unaffected response rates.
2001 Jul
Genetic damage by bifunctional agents in repair-active pre-meiotic stages of Drosophila males.
2001 Jul 1
A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma.
2001 Jul 6
Treatment options in Waldenström's macroglobulinaemia: the role of the purine analogues.
2001 Jun
UCN-01 induces cytotoxicity toward human CLL cells through a p53-independent mechanism.
2001 Jun
[Chronic lymphatic leukemia. 3. The concrete case].
2001 Jun 8
[Chronic lymphocytic leukemia. 2. Therapy].
2001 Jun 8
Acquired Factor VIII autoantibody: four cases demonstrating the heterogenous nature of this condition and problems involved in diagnosis and treatment.
2001 Mar
A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children.
2001 Mar
Treatment of elderly patients with intermediate- and high-grade non-Hodgkin's lymphoma: a retrospective population-based study.
2001 Mar
Hypercalcaemia associated with chronic lymphocytic leukaemia in a Giant Schnauzer.
2001 May
Does intensive treatment with high dose chlorambucil and prednisone as first line and cladribine as second line influence the survival of the patients with chronic lymphocytic leukemia?
2001 May
Treatment of myelopathy in Sjögren syndrome with a combination of prednisone and cyclophosphamide.
2001 May
Induction of mutant lymphocytes in cyclophosphamide- and chlorambucil-treated patients.
2001 May
ChlVPP alternating with PABlOE is superior to PABlOE alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation/Central Lymphoma Group randomized controlled trial.
2001 May 18
2-[N1-2-pyrimidyl-aminobenzenesulfonamido] ethyl 4-bis(2-chloroethyl) aminophenyl butyrate: a potent antitumor agent.
2001 May 7
Prediction of subsequent relapse in children with steroid-sensitive nephrotic syndrome.
2001 Nov
Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype.
2001 Nov
Caspase 8 activation independent of Fas (CD95/APO-1) signaling may mediate killing of B-chronic lymphocytic leukemia cells by cytotoxic drugs or gamma radiation.
2001 Nov 1
A novel kind of antitumour drugs using sulfonamide as parent compound.
2001 Nov-Dec
Lymphoplasmacytic lymphoma/immunocytoma: towards a disease-targeted treatment?
2001 Sep
[Vascular purpura in a patient with severe sarcoptic acariasis].
2001 Sep
Autologous plasma activates Akt/protein kinase B and enhances basal survival and resistance to DNA damage-induced apoptosis in B-chronic lymphocytic leukaemia cells.
2001 Sep
A case of Behćet's disease complicated by visceral Leishmaniasis and myelodysplasia: clinical considerations.
2001 Sep
Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue.
2001 Sep 1
Novel bicistronic retroviral vector expressing gamma-glutamylcysteine synthetase and the multidrug resistance protein 1 (MRP1) protects cells from MRP1-effluxed drugs and alkylating agents.
2001 Sep 20
Chronic lymphocytic leukaemia.
2001 Sep-Oct
Cutaneous necrobiotic xanthogranuloma (NXG)--successfully treated with low dose chlorambucil.
2001 Sep-Oct
Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy.
2002 Jan
Sciatica or spinal lymphoma.
2002 Jan
Efficacy and safety of chlorambucil in intractable noninfectious uveitis: the Massachusetts Eye and Ear Infirmary experience.
2002 Jan
Developments in the treatment of uveitis.
2002 Jan
Patents

Patents

05852011
2
07910607
3
08530434
1
JP2002511777A
420
JP2003529540A
50
JP2005503151A
5
JP2005507376A
6
JP2005519871A
30
JP2006528196A
42
JP2008501654A
33
JP2008510829A
14
JP2008519861A
32
JP2009513567A
66
JP2010506837A
76
JP2011519819A
8
JP2011524416A
146
JP4350148B2
5
JPH1112175A
3

Sample Use Guides

In Vivo Use Guide
0.1 to 0.2 mg/kg body weight daily for 3 to 6 weeks
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: Chronic lymphocytic leukaemia cells were treated
The inhibition of 3H-thymidine incorporation into the DNA of mitogen-stimulated lymphocytes from patients with chronic lymphocytic leukaemia by chlorambucil was measured in vitro. For the lymphocytes from the untreated patients the mean ID50 was 3.1 ug/ml.
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:33:31 GMT 2025
Edited
by admin
on Mon Mar 31 17:33:31 GMT 2025
Record UNII
18D0SL7309
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LEUKERAN
Preferred Name English
CHLORAMBUCIL
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INN  
Official Name English
CB-1348
Code English
CHLORAMBUCIL [JAN]
Common Name English
CHLORAMBUCIL [EP MONOGRAPH]
Common Name English
CHLORAMBUCIL [IARC]
Common Name English
4-(P-(BIS(2-CHLOROETHYL)AMINO)PHENYL)BUTYRIC ACID
Common Name English
CHLORAMBUCILUM [WHO-IP LATIN]
Common Name English
Chlorambucil [WHO-DD]
Common Name English
AMBOCHLORIN
Common Name English
NSC-3088
Code English
CHLORAMBUCIL [VANDF]
Common Name English
ECLORIL
Common Name English
BENZENEBUTANOIC ACID, 4-(BIS(2-CHLOROETHYL)AMINO)-
Common Name English
LYMPHOLYSIN
Common Name English
CHLORAMBUCIL [MART.]
Common Name English
CHLORAMBUCIL [HSDB]
Common Name English
CHLORAMBUCIL [WHO-IP]
Common Name English
NCI-3088
Code English
CHLORAMBUCIL [USP-RS]
Common Name English
chlorambucil [INN]
Common Name English
CHLORAMBUCIL [ORANGE BOOK]
Common Name English
CHLORAMBUCIL [MI]
Common Name English
CHLORAMBUCIL [USP MONOGRAPH]
Common Name English
Classification Tree Code System Code
LIVERTOX NBK548207
Created by admin on Mon Mar 31 17:33:31 GMT 2025 , Edited by admin on Mon Mar 31 17:33:31 GMT 2025
NDF-RT N0000175558
Created by admin on Mon Mar 31 17:33:31 GMT 2025 , Edited by admin on Mon Mar 31 17:33:31 GMT 2025
NDF-RT N0000000236
Created by admin on Mon Mar 31 17:33:31 GMT 2025 , Edited by admin on Mon Mar 31 17:33:31 GMT 2025
NCI_THESAURUS C697
Created by admin on Mon Mar 31 17:33:31 GMT 2025 , Edited by admin on Mon Mar 31 17:33:31 GMT 2025
WHO-VATC QL01AA02
Created by admin on Mon Mar 31 17:33:31 GMT 2025 , Edited by admin on Mon Mar 31 17:33:31 GMT 2025
WHO-ATC L01AA02
Created by admin on Mon Mar 31 17:33:31 GMT 2025 , Edited by admin on Mon Mar 31 17:33:31 GMT 2025
WHO-ESSENTIAL MEDICINES LIST 8.2
Created by admin on Mon Mar 31 17:33:31 GMT 2025 , Edited by admin on Mon Mar 31 17:33:31 GMT 2025
Code System Code Type Description
WIKIPEDIA
CHLORAMBUCIL
Created by admin on Mon Mar 31 17:33:31 GMT 2025 , Edited by admin on Mon Mar 31 17:33:31 GMT 2025
PRIMARY
EVMPD
SUB06172MIG
Created by admin on Mon Mar 31 17:33:31 GMT 2025 , Edited by admin on Mon Mar 31 17:33:31 GMT 2025
PRIMARY
CAS
305-03-3
Created by admin on Mon Mar 31 17:33:31 GMT 2025 , Edited by admin on Mon Mar 31 17:33:31 GMT 2025
PRIMARY
MERCK INDEX
m3343
Created by admin on Mon Mar 31 17:33:31 GMT 2025 , Edited by admin on Mon Mar 31 17:33:31 GMT 2025
PRIMARY Merck Index
EPA CompTox
DTXSID7020263
Created by admin on Mon Mar 31 17:33:31 GMT 2025 , Edited by admin on Mon Mar 31 17:33:31 GMT 2025
PRIMARY
ECHA (EC/EINECS)
206-162-0
Created by admin on Mon Mar 31 17:33:31 GMT 2025 , Edited by admin on Mon Mar 31 17:33:31 GMT 2025
PRIMARY
RS_ITEM_NUM
1106001
Created by admin on Mon Mar 31 17:33:31 GMT 2025 , Edited by admin on Mon Mar 31 17:33:31 GMT 2025
PRIMARY
IUPHAR
7143
Created by admin on Mon Mar 31 17:33:31 GMT 2025 , Edited by admin on Mon Mar 31 17:33:31 GMT 2025
PRIMARY
ChEMBL
CHEMBL515
Created by admin on Mon Mar 31 17:33:31 GMT 2025 , Edited by admin on Mon Mar 31 17:33:31 GMT 2025
PRIMARY
HSDB
3026
Created by admin on Mon Mar 31 17:33:31 GMT 2025 , Edited by admin on Mon Mar 31 17:33:31 GMT 2025
PRIMARY
FDA UNII
18D0SL7309
Created by admin on Mon Mar 31 17:33:31 GMT 2025 , Edited by admin on Mon Mar 31 17:33:31 GMT 2025
PRIMARY
CHEBI
28830
Created by admin on Mon Mar 31 17:33:31 GMT 2025 , Edited by admin on Mon Mar 31 17:33:31 GMT 2025
PRIMARY
DRUG BANK
DB00291
Created by admin on Mon Mar 31 17:33:31 GMT 2025 , Edited by admin on Mon Mar 31 17:33:31 GMT 2025
PRIMARY
RXCUI
2346
Created by admin on Mon Mar 31 17:33:31 GMT 2025 , Edited by admin on Mon Mar 31 17:33:31 GMT 2025
PRIMARY RxNorm
PUBCHEM
2708
Created by admin on Mon Mar 31 17:33:31 GMT 2025 , Edited by admin on Mon Mar 31 17:33:31 GMT 2025
PRIMARY
INN
603
Created by admin on Mon Mar 31 17:33:31 GMT 2025 , Edited by admin on Mon Mar 31 17:33:31 GMT 2025
PRIMARY
NSC
3088
Created by admin on Mon Mar 31 17:33:31 GMT 2025 , Edited by admin on Mon Mar 31 17:33:31 GMT 2025
PRIMARY
DAILYMED
18D0SL7309
Created by admin on Mon Mar 31 17:33:31 GMT 2025 , Edited by admin on Mon Mar 31 17:33:31 GMT 2025
PRIMARY
NCI_THESAURUS
C362
Created by admin on Mon Mar 31 17:33:31 GMT 2025 , Edited by admin on Mon Mar 31 17:33:31 GMT 2025
PRIMARY
MESH
D002699
Created by admin on Mon Mar 31 17:33:31 GMT 2025 , Edited by admin on Mon Mar 31 17:33:31 GMT 2025
PRIMARY
SMS_ID
100000081577
Created by admin on Mon Mar 31 17:33:31 GMT 2025 , Edited by admin on Mon Mar 31 17:33:31 GMT 2025
PRIMARY
DRUG CENTRAL
588
Created by admin on Mon Mar 31 17:33:31 GMT 2025 , Edited by admin on Mon Mar 31 17:33:31 GMT 2025
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
CHLORAMBUCIL
Created by admin on Mon Mar 31 17:33:31 GMT 2025 , Edited by admin on Mon Mar 31 17:33:31 GMT 2025
PRIMARY Description: A white or almost white, crystalline or slightly granular powder. Solubility: Practically insoluble in water; freely soluble in ethanol (~750 g/l) TS and acetone R. Category: Cytotoxic drug. Storage: Chlorambucil should be kept in a well-closed container, protected from light. Additional information: CAUTION: Chlorambucil must be handled with care, avoiding contact with the skin and inhalation of airborne particles. Definition: Chlorambucil contains not less than 98.0% and not more than 101.0% of C14H19Cl2NO2, calculated with reference to the anhydrous substance.
Related Record Type Details
Structure of CHLORAMBUCIL
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
Structure of CHLORAMBUCIL
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
USP
MULTIDRUG RESISTANCE PROTEIN 1
TRANSPORTER -> SUBSTRATE
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Related Record Type Details
Structure of N,N-BIS(2-CHLOROETHYL)-P-AMINOPHENYLACETIC ACID
METABOLITE ACTIVE -> PARENT
Has antineoplastic activity
Related Record Type Details
Structure of ORTHO-CHLORAMBUCIL
IMPURITY -> PARENT
Structure of HYDROXY CHLORAMBUCIL
IMPURITY -> PARENT
Structure of CHLORAMBUCIL TRIMER ESTER
IMPURITY -> PARENT
Structure of 4-(4-((2-((BIS(2-CHLOROETHOXY)PHOSPHORYL)OXY)ETHYL)(2-CHLOROETHYL)AMINO)PHENYL)BUTANOIC ACID
IMPURITY -> PARENT
Structure of CHLORAMBUCIL CHLOROETHYL ESTER
IMPURITY -> PARENT
Structure of MONOCHLOROETHYL CHLORAMBUCIL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of CHLORAMBUCIL DIMER ESTER
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of CHLORAMBUCIL
ACTIVE MOIETY
A white or almost white, crystalline or slightly granular powder.
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966